Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Part A: Change From Baseline in LDL-C at Week 12

LDL-C was quantified using the ultracentrifugation method.

Time frame: Baseline and Week 12

Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

Time frame: Baseline and Week 12

Part A: Percent Change From Baseline in Apolipoprotein B at Week 12

Time frame: Baseline and Week 12

Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12

Time frame: Baseline and Week 12

Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

Time frame: Baseline and Week 12

Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12

LDL-C was quantified using the ultracentrifugation method.

Time frame: Baseline and Week 12

Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12